PP289 - SUPPLEMENT ADHERENCE AND ITS ASSOCIATION WITH CHANGES IN PROTEIN REQUIREMENT COVERAGE AND FUNCTIONAL OUTCOMES: AN EXPLORATORY ANALYSIS OF A MULTIMODAL INTERVENTION STUDY IN PATIENTS WITH ADVANCED CANCER
PP289
SUPPLEMENT ADHERENCE AND ITS ASSOCIATION WITH CHANGES IN PROTEIN REQUIREMENT COVERAGE AND FUNCTIONAL OUTCOMES: AN EXPLORATORY ANALYSIS OF A MULTIMODAL INTERVENTION STUDY IN PATIENTS WITH ADVANCED CANCER
L. Gafner1,*, E. G. Gerrits1,2, M. Ruehlin1, Y. Krepp3, R. Benkelmann3, B. Rohrbach4, C. J. Ackermann4, A. Tan1, M. Schmocker5, D. Gisi5, M. Pless6, C. Britschgi6, P. E. Ballmer7,8, L. J. Storck1,3
1Center of Nutritional Medicine and Therapy, 2Clinic for Internal Medicine, Kantonsspital Winterthur, Winterthur, Switzerland, 3Medizinische Klinik, Klinikum Konstanz, Konstanz, Germany, 4Oncology and Hematology, Spital Thun, Thun, 5Institute for Therapy and Rehabilitation, 6Clinic for Medical Oncology and Hematology, Kantonsspital Winterthur, 7Past President, GESKES-SSNC, 8Praxis am Graben, Winterthur, Switzerland
Rationale: Patients with advanced cancer are at high risk of malnutrition. Multimodal programs may improve quality of life (QoL), nutritional status, dietary intake, physical function, and fatigue.
Methods: In a randomized multicenter trial, we tested the effect of a nutrition and exercise program, including a protein supplement, on QoL (primary endpoint) in patients with advanced cancer.
In this exploratory analysis, we assessed correlations between supplement adherence and changes in protein requirement coverage, handgrip strength, 60-s sit-to-stand performance, and skeletal muscle mass within the intervention group.
Because some data were non-normally distributed (Shapiro-Wilk), Pearson and Spearman correlations were calculated for robustness.
Results: Supplement adherence showed a moderate-to-strong correlation with changes in protein requirement coverage (Pearson: r=0.531, p=0.011; Spearman: ρ=0.524, p=0.012; n=22) and also a correlation when considering protein intake excluding the study supplement, reaching significance only in Spearman analysis (Pearson: r=0.402, p=0.064; Spearman: ρ=0.423, p=0.049; n=22). Supplement adherence showed no significant correlation with changes in handgrip strength, despite a moderate effect size (Pearson: r=0.369, p=0.053; Spearman: ρ=0.304, p=0.116; n=28). No significant correlations were observed for changes in 60-s sit-to-stand performance, or skeletal muscle mass.
Conclusion: Higher supplement adherence correlated with greater protein requirement coverage even when protein intake from the supplement was excluded, suggesting broader adherence to the overall nutritional intervention. No significant correlations were found for functional outcomes or skeletal muscle mass. This may reflect their multifactorial nature, limited statistical power, or short intervention duration.
Disclosure of Interest: L. Gafner Grant / Research Support from: FresuCare AG, E. Gerrits: None declared, M. Ruehlin: None declared, Y. Krepp: None declared, R. Benkelmann: None declared, B. Rohrbach: None declared, C. Ackermann Other: Consultant and travel support: MSD, Roche, AstraZeneca, Daiichi Sankyo, Pfizer, A. Tan: None declared, M. Schmocker: None declared, D. Gisi: None declared, M. Pless Consultant for: Bayer, MSD, Boehringer Ingelheim, Amgen, Novartis, Takeda, Speakers Bureau of: Novartis, Nestlé, Sanofi, Roche, MSD, Vifor, AstraZeneca, Dr. Ouwerkerk, Other: Travel Support by Daichii Sankyo, C. Britschgi Grant / Research Support from: Bayer, Consultant for: AstraZeneca, Pfizer, Roche, Takeda, Janssen-Cilag, Boehringer-Ingelheim, Merck KGaA, Sanofi, Other: Travel, Accommodations, Expenses by AstraZeneca, Takeda, Amgen, P. Ballmer: None declared, L. Storck: None declared